ProCE Banner Activity

Optimizing Patient Outcomes and Quality of Life With Adjuvant Abemaciclib in HR+/HER2- Early Breast Cancer Through Adverse Event Management

Clinical Thought

Read about how managing the adverse events associated with adjuvant abemaciclib can affect patients with HR-positive/HER2‑negative early breast cancer.

Released: January 31, 2023

Expiration: January 30, 2024

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Julia A LaBarbera, MSN, RN, AGACNP-BC

Nurse Practitioner
UCLA Hematology Oncology
Santa Monica, California

Julia LaBarbera, MSN, RN, AGACNP-BC: consultant/advisor/speaker: Bio-Theradiagnostics, Cancer Network/MJH Life Sciences.